Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Net Cash Flow (2020 - 2023)

Cullinan Therapeutics has reported Net Cash Flow over the past 4 years, most recently at $33.6 million for Q4 2023.

  • Quarterly results put Net Cash Flow at $33.6 million for Q4 2023, up 138.83% from a year ago — trailing twelve months through Dec 2023 was -$57.7 million (down 159.89% YoY), and the annual figure for FY2025 was $5.3 million, up 134.53%.
  • Net Cash Flow for Q4 2023 was $33.6 million at Cullinan Therapeutics, up from -$77.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for CGEM hit a ceiling of $277.4 million in Q2 2022 and a floor of -$169.9 million in Q2 2021.
  • Median Net Cash Flow over the past 4 years was -$13.8 million (2020), compared with a mean of $2.2 million.
  • Peak annual rise in Net Cash Flow hit 801.47% in 2021, while the deepest fall reached 3069.18% in 2021.
  • Cullinan Therapeutics' Net Cash Flow stood at $126.9 million in 2020, then tumbled by 122.33% to -$28.3 million in 2021, then plummeted by 205.34% to -$86.5 million in 2022, then skyrocketed by 138.83% to $33.6 million in 2023.
  • The last three reported values for Net Cash Flow were $33.6 million (Q4 2023), -$77.0 million (Q3 2023), and $19.7 million (Q2 2023) per Business Quant data.